Compare Quest Diagnostics Inc (DGX) vs Logitech International SA (LOGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Logitech International SA — how do they compare? Quest Diagnostics Inc trades at $204.59 (market cap $22.80B), while Logitech International SA trades at $100.24 (market cap $14.53B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Logitech International SA pays the higher dividend (1.69%). Which is the better fit depends on your goals.
| DGX | LOGI | |
|---|---|---|
Market Cap | $22.80B | $14.53B |
Sector | Health | Technology |
52-Week High | $216.02 | $126.69 |
52-Week Low | $166.42 | $85.84 |
Enterprise Value | $28.82B | $12.88B |
Dividend Yield | 1.67% | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Logitech (LOGI) trades at $102.22, up 0.26% on the day, with a bullish technical signal supported by moving averages. The company demonstrates strong profitability with a net margin of 14.69% and ROE of 32.78%, while recent quarters show consistent earnings beats. New product launches and a partnership with Call of Duty: Modern Warfare 4 highlight ongoing growth initiatives. Cash flow trends remain positive with 2026 operating cash flow projected at $1.0 billion.
Outlook is cautiously optimistic given mixed analyst ratings but solid fundamentals. Upside exists to the $113 consensus target, though competitive pressures and reliance on consumer spending pose risks. The stock offers value if execution on B2B and AI products drives margin expansion as anticipated.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →
